Exalenz Announces Third Quarter 2018 Financial Results
November 15, 2018 07:00 ET
|
Exalenz Bioscience Ltd.
Third quarter 2018 revenue increased 25% to $3.2 million, compared with $2.5 million in same period in 2017 Third quarter 2018 gross profit increased 60% compared to same period in 2017 ...
Exalenz to Present Positive Clinical Data for the Breath ID® 13C-Methacetin Breath Test System at the Liver Meeting® 2018
November 05, 2018 01:30 ET
|
Exalenz Bioscience Ltd.
MODI’IN, Israel and MANASQUAN, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE: EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...
Exalenz Announces Second Quarter 2018 Financial Results
August 31, 2018 10:00 ET
|
Exalenz Bioscience Ltd.
Second quarter 2018 revenue increased 53% to $3.4 million, compared with $2.2 million in same period in 2017The Company estimates total revenues for 2018 to reach $13 -14 million, an increase of 37 –...
Exalenz Bioscience’s Non-Invasive BreathID® Test to be Evaluated in Two Bristol-Myers Squibb Phase 2b Clinical Trials in Adult Patients with NASH
July 10, 2018 07:30 ET
|
Exalenz Bioscience Ltd.
Studies will use BreathID 13C-methacetin breath test to evaluate patient response to therapy MODI’IN, Israel and MANASQUAN, N.J., July 10, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd....
Exalenz Announces Confidential Submission of Draft Registration Statement for Initial Public Offering
June 18, 2018 08:00 ET
|
Exalenz Bioscience Ltd.
MODI’IN, Israel and MANASQUAN, N.J., June 18, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...
Exalenz Bioscience Appoints Roy Golan as President and Chief Financial Officer
April 30, 2018 07:30 ET
|
Exalenz Bioscience Ltd.
Healthcare Industry Veteran Brings Track Record of Success MODI’IN, Israel and MANASQUAN, N.J., April 30, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and...
Exalenz Bioscience’s BreathID® Hp & BreathID Hp Lab Systems Receive FDA Clearance for Diagnosis of Helicobacter pylori Testing in Pediatric Patients
March 13, 2018 09:00 ET
|
Exalenz Bioscience Ltd.
MODI'IN, Israel and MANASQUAN, N.J., March 13, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...
Exalenz Announces Fourth Quarter and Full Year 2017 Financial Results
March 12, 2018 09:00 ET
|
Exalenz Bioscience Ltd.
- 2017 revenue increased 127% to $9.5 million, compared with $4.2 million in 2016 - - Fourth quarter 2017 revenue increased 161% compared with same period in 2016 - MODI’IN, Israel and MANASQUAN,...
Exalenz Bioscience to Participate in Upcoming Investor Conferences
March 09, 2018 08:00 ET
|
Exalenz Bioscience Ltd.
MODI’IN, Israel and MANASQUAN, N.J., March 09, 2018 (GLOBE NEWSWIRE) -- Exalenz Bioscience Ltd. (TASE:EXEN), a leader in developing and marketing non-invasive medical devices for diagnosing and...
Exalenz Bioscience Announces Positive Clinical Trial Results For the Diagnosis of Clinically Significant Portal Hypertension in NASH Patients
January 24, 2018 07:30 ET
|
Exalenz Bioscience Ltd.
Easy-to-administer, noninvasive BreathID® test offers multiple advantages over alternative invasive detection methods Potential 2020 entry to an addressable U.S. market of millions of NASH patients ...